Evidence map›Paper›PMID 39590157›Full record

ArticleCurrent oncology (Toronto, Ont.)2024

Facilitation of Enrollment onto Cancer Clinical Trials Using a Novel Navigator-Assisted Program: A Cross-Sectional Study.

Mahmoud Hossami, Rhonda Abdel-Nabi, Farwa Zaib, Kayla Touma, Renee Nassar, Sanghyuk Claire Rim, Milica Paunic, Olla Hilal, Pratham Gupta, Roaa Hirmiz and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Current oncology (Toronto, Ont.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Mahmoud HossamiFaculty of Biomedical Science, University of Windsor, Windsor, ON N9B 3P4, Canada.
Rhonda Abdel-NabiFaculty of Biomedical Science, University of Windsor, Windsor, ON N9B 3P4, Canada.ORCID 0009-0008-6377-8932
Farwa ZaibDepartment of Oncology, Western University, Windsor Campus, Windsor, ON N8W 2X3, Canada.
Kayla ToumaFaculty of Biomedical Science, University of Windsor, Windsor, ON N9B 3P4, Canada.
Renee NassarDepartment of Oncology, Western University, Windsor Campus, Windsor, ON N8W 2X3, Canada.ORCID 0009-0001-2124-3293
Sanghyuk Claire RimDepartment of Oncology, Western University, Windsor Campus, Windsor, ON N8W 2X3, Canada.
Milica PaunicFaculty of Biomedical Science, University of Windsor, Windsor, ON N9B 3P4, Canada.ORCID 0009-0002-3172-6931
Olla HilalDepartment of Oncology, Western University, Windsor Campus, Windsor, ON N8W 2X3, Canada.ORCID 0009-0008-9419-8957
Pratham GuptaDepartment of Oncology, Western University, Windsor Campus, Windsor, ON N8W 2X3, Canada.
Roaa HirmizClinical Trials Navigator Inc., Windsor, ON N8W 2X3, Canada.
Michael ToumaSchool of Medicine, Griffith University, Gold Coast, QLD 4111, Australia.
Govana SadikFaculty of Biomedical Science, University of Windsor, Windsor, ON N9B 3P4, Canada.
Emmanuel AkingbadeFaculty of Biomedical Science, University of Windsor, Windsor, ON N9B 3P4, Canada.
Depen SharmaFaculty of Biomedical Science, University of Windsor, Windsor, ON N9B 3P4, Canada.ORCID 0009-0002-5030-7230
Swati KaliaDepartment of Oncology, Western University, Windsor Campus, Windsor, ON N8W 2X3, Canada.
Rija FatimaFaculty of Biomedical Science, University of Windsor, Windsor, ON N9B 3P4, Canada.
Anthony LuginaahDepartment of Oncology, Western University, Windsor Campus, Windsor, ON N8W 2X3, Canada.ORCID 0000-0002-1037-2292
Ibrahim MohamedDepartment of Oncology, Western University, Windsor Campus, Windsor, ON N8W 2X3, Canada.
Rong LuoFaculty of Biomedical Science, University of Windsor, Windsor, ON N9B 3P4, Canada.
Megan DelisleDepartment of Surgery, University of Manitoba, Winnipeg, MB R3E 0V9, Canada.
Caroline HammFaculty of Biomedical Science, University of Windsor, Windsor, ON N9B 3P4, Canada.ORCID 0000-0003-1326-2088

Funding

CIHR 505608
6 · The paper itself

Abstract

introductionClinical trials are essential to the advancement of clinical therapies that improve the outcomes of people with cancer. However, enrollment in clinical trials remains a challenge. The Clinical Trial Navigator [CTN] Program was designed to address the current gap in the cancer care journey by assisting with the clinical trials search process.

methodsBetween March 2019 and July 2024, applicants of the CTN program included people with cancer, their family members, and/or their care team. Applicants entered the CTN program through a REDCap

resultsA total of 445 people with cancer applied to the CTN program during the study. Of the 262 patients with referral and enrollment information, a trial referral occurred in 27.5% [n = 72]. Of the 72 patients who were referred to a clinical trial, 13 [18.1%] were enrolled, 9 [12.5%] are pending enrollment, and 50 [69.4%] were not enrolled. We identified a potential trial for 88% of applicants, with a median of one potential trial per patient. Physicians were highly involved as applicants.

interpretationThe CTN program is successful in searching for clinical trials for people with cancer. Ongoing implementation into other Canadian sites, assessments of patient-reported outcomes, website and social media campaigns, and research into the factors that impact referral and enrollment are underway.

Indexed as

Clinical Trials as TopicNeoplasmsPatient SelectionAdultAgedCross-Sectional StudiesFemaleHumansMaleMiddle AgedPatient Navigationcancerclinical trials accrualnavigator

Identifiers

PMID39590157
PMCPMC11593092

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.